Home » Stocks » Codiak BioSciences

Codiak BioSciences, Inc. (CDAK)

Stock Price: $9.50 USD 0.07 (0.74%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 176.61M
Revenue (ttm) 622
Net Income (ttm) -94.46M
Shares Out 18.59M
EPS (ttm) -5.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $9.50
Previous Close $9.43
Change ($) 0.07
Change (%) 0.74%
Day's Open 9.55
Day's Range 9.13 - 9.66
Day's Volume 132,878
52-Week Range 9.05 - 14.40

More Stats

Market Cap 176.61M
Enterprise Value 172.99M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 18.59M
Float 8.03M
EPS (basic) n/a
EPS (diluted) -5.08
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 283,930.87
PB Ratio n/a
Revenue 622
Operating Income n/a
Net Income -94.46M
Free Cash Flow n/a
Net Cash 3.61M
Net Cash / Share 0.19
Gross Margin -9,503.70%
Operating Margin n/a
Profit Margin -15,186,977.49%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit0.39-
Operating Income-80.15-46.44
Net Income-77.96-44.54
Shares Outstanding2.992.52
Earnings Per Share-30.66-23.07
Operating Cash Flow-1.70-30.57
Capital Expenditures-10.48-1.82
Free Cash Flow-12.18-32.39
Cash & Equivalents83.7588.86
Total Debt9.57-
Net Cash / Debt74.1888.86
Book Value-193-109
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Codiak BioSciences, Inc.
Country United States
Employees 101
CEO Douglas E. Williams

Stock Information

Ticker Symbol CDAK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CDAK
IPO Date October 14, 2020


Codiak BioSciences is harnessing exosomes?natural intercellular messengers?to pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.